Zydus Cadila gets USFDA nod for overactive bladder treatment drug

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Solifenacin Succinate tablets, in the strengths of 5 mg and 10 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3o8gWVu
via IFTTT